Status:

COMPLETED

A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants

Lead Sponsor:

Janssen Research & Development, LLC

Conditions:

Healthy

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to evaluate the pharmacokinetic (what the body does to the medication) comparability of guselkumab in lyophilized and liquid formulations. Also to evaluate pharmacokinetic...

Detailed Description

This is an open-label (all people know the identity of the intervention), randomized (the study medication is assigned by chance), parallel study (each group of participants will be treated at the sam...

Eligibility Criteria

Inclusion

  • Healthy participant with no clinically significant abnormalities
  • Have a weight in the range of 60 kg to 90 kg for male participants; have a weight in the range of 50 kg to 80 kg for female participants
  • Have a body mass index (BMI) of 18.5 kg/m2 to 29.0 kg/m2
  • Agrees to protocol-defined use of effective contraception

Exclusion

  • Participant has a history of any clinically significant medical illness including liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances, ophthalmological disorders, neoplastic disease, urinary tract diseases, or dermatological disease
  • Currently have any known malignancy or have a history of malignancy
  • Participant has a known or suspected intolerance or hypersensitivity to any biologic medication or known allergies or clinically significant reactions to murine, chimeric, or human proteins to monoclonal antibodies or antibody fragments
  • Have had a Bacillus Calmette-Guérin (BCG) vaccination within 12 months of screening

Key Trial Info

Start Date :

May 9 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 9 2013

Estimated Enrollment :

141 Patients enrolled

Trial Details

Trial ID

NCT01866007

Start Date

May 9 2013

End Date

October 9 2013

Last Update

January 27 2020

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Tempe, Arizona, United States

2

Lincoln, Nebraska, United States

3

Neptune City, New Jersey, United States